Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine - LARVOL DELTA

HLA-A*11:01-restricted HPV16/18 E6/E7 peptides with stable MHC binding identify prophylactic and therapeutic CD8+ T cell vaccine candidates for Asian populations (ESMO-IO 2025) - "Background Cervical cancer largely caused by high-risk HPV strains accounts for over 170000 deaths annually despite advances in preventive vaccines (e.g Gardasil-9 and Cervarix). 2 in silico hits (1 HPV18 E6 and 1 HPV18 E7) did not bind stably to soluble HLA-A*11:01. Work is ongoing to validate functional immunogenicity of these 15 peptides.Conclusions In silico predictions and in vitro binding assay identified 15 E6/E7 epitopes from HPV16/18, laying the foundation for prophylactic and therapeutic cancer vaccine development in HLA-A*11:01-prevalent populations.Legal entity responsible for the study National Cancer Centre Singapore."

Clinical • Cervical Cancer • Oncology • Solid Tumor • CD8 • IFNG • TNFA

Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial. (PubMed, NPJ Vaccines) - "Prophylactic human papillomavirus vaccines such as Cervarix® and Gardasil®9 induce robust and sustained antibody responses over time...By Month 36, MBC responses to both vaccines for both HPV16 and 18 were similar across all dosing arms. The clinical significance of the dose response remains to be evaluated; however, the presence of MBCs in the circulation after 3 years with a single vaccine dose is encouraging in terms of generating long-lasting protection with a one-dose vaccination strategy."

Journal • Oncology

Cost-effectiveness of HPV catch-up vaccination program in women aged 13-24 years in a middle income country. (PubMed, J Gynecol Oncol) - "All catch-up vaccination programs for women aged 13 to 24 years produce additional health benefits and reduce healthcare costs. Vaccination with 9vHPV was considered the most cost-effective option."

HEOR • Journal • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Chlamydia trachomatis Infection and Its Association with Human Papillomavirus Among Adolescent Girls and Young Women of Eastern Cape, South Africa. (PubMed, Epidemiologia (Basel)) - "There was a high burden of C. trachomatis and HPV coinfection. C. trachomatis coinfection influenced HPV genotype prevalence and distribution, including those that are targeted by the current commercial HPV vaccines, suggesting that the high burden of C. trachomatis among AGYW may pose challenges to the ongoing HPV vaccination program. Integrated STI screening and prevention strategies are needed in rural South African settings."

Journal • Infectious Disease • Oncology

Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "The evidence in this network meta-analysis of HPV vaccines is based on extensive searches and analyses. There is evidence from randomised controlled trials that HPV vaccination reduces the risk of pre-cancerous outcomes such as CIN2+ and anogenital warts. No data were available for cervical cancer or other cancer outcomes, and no data on pre-cancer outcomes were available for vaccination under age 15 years. There were no safety concerns noted in the studies."

Clinical • Journal • Retrospective data • Review • Cervical Cancer • Dermatology • Human Papillomavirus Infection • Infectious Disease • Oncology • Penile Cancer • Solid Tumor

VERY HIGH PREVALENCE OF HIGH-RISK HPV AMONGST ADOLESCENT GIRLS AND YOUNG WOMEN IN A HIGH HIV BURDEN RURAL AREA OF SOUTH AFRICA (IPVC 2025) - "South Africa introduced national HPV vaccination for Grade 4 girls (age ≥9) in 2014, with the bivalent vaccine Cervarix®... HPV, including HR HPV, was extremely common in AGYW in rural South Africa. There is an urgent need to roll out the 9-valent vaccine and ensure that cervical screening programmes are effectively implemented, particularly for women living with HIV."

Clinical • Cervical Cancer • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Solid Tumor

HUMAN PAPILLOMAVIRUS VACCINE LANDSCAPE (IPVC 2025) - " Since 2006, WHO has approved five HPV vaccines: three bivalent vaccines (Cervarix, Cecolin, and Walrinvax); one quadrivalent vaccine (Gardasil); and one nonavalent vaccine (Gardasil 9). Two domestically licensed vaccines are available in Bangladesh (HPvax) and India (Cervavac)... Global vaccine introduction has made good progress in recent years. Countries that have introduced the vaccine subnationally—such as China, Russia, and India—have large populations and wide geographical areas. The vaccine landscape in China is changing rapidly with more low-cost vaccines becoming available, that will likely further influence global vaccine availability."

Cervical Cancer • Genito-urinary Cancer • Penile Cancer • Solid Tumor

GLOBE-HPV: HPV VACCINE COVERAGE AMONG ADOLESCENT GIRLS FOLLOWING A NATIONAL VACCINATION PROGRAM: A COMMUNITY-BASED CROSS-SECTIONAL STUDY IN BANGLADESH (IPVC 2025) - "The campaign targeted girls studying in grades V to IX or those out-of-school aged 10-14 years, with a single dose of the bivalent vaccine (Cervarix®, GSK)... Our findings indicate lower HPV vaccination coverage in the study areas compared to national coverage (88.9%) following completion of all phases of the campaign. Significant disparities in coverage were observed between girls living in an urban slum and those living in a rural area. These findings highlight the urgent need for targeted strategies to improve awareness, address vaccine hesitancy, and strengthen age-specific community outreach efforts for out-of-school girls."

Observational data

ACTIVELY PROMOTE THE VACCINATION OF HUMAN PAPILLOMAVIRUS VACCINE IN CHINA (IPVC 2025) - " At present, there are 5 HPV vaccines in China, including bivalent vaccine (Cervarix, Cecolin and Wozehui), 4-valent and 9-valent vaccine (Gardasil 4 and 9), for women aged 9 to 45 ys,and for men aged 9 to 26y (4-valent), and 16 to 26ys(9-valent ). Now we have face big challenges to eliminate cervical cancer, With the combination of HPV vaccination and cervical cancer screening, China is accelerating the elimination of cervical cancer."

Cervical Cancer • Infectious Disease • Solid Tumor

HPV VACCINE EFFECTIVENESS AGAINST CERVICAL CANCER AND PRECANCER IN JAPAN: A TEST-NEGATIVE CASE–CONTROL STUDY (IPVC 2025) - "Introduction: Japan's human papillomavirus (HPV) immunization program for girls aged 12-16 years started in 2010 with the 2-valent vaccine (Cervarix). The 4-valent vaccine (Gardasil) was next introduced to the immunization program in 2011, while the 9-valent vaccine (Gardasil 9) was just recently introduced in 2023... These results indicate the real-world effectiveness of the 2- or 4-valent HPV vaccines after the introduction of the national immunization program in Japan."

Clinical • Cervical Cancer • Gynecology • Oncology • Solid Tumor

HPV VACCINE IN CHINA: PROGRESS AND CHALLENGES TOWARD THE NATIONAL IMMUNIZATION PROGRAM (IPVC 2025) - " At present, five HPV vaccines are commercially available in China, including three bivalent vaccines (Cervarix, Cecolin, and Walrinvax), one quadrivalent vaccine (Gardasil), and one nonavalent vaccine (Gardasil-9). Despite the increasing availability of HPV vaccines in China and the gradual expansion of provincial-level vaccination programs, national coverage remains critically low, particularly among the target age group of 9–14 years. Accelerating the integration of HPV vaccination into the national program, alongside strategies to improve affordability, accessibility, and public awareness, will be essential for China to close the gap with global progress and to advance toward cervical cancer elimination."

Cervical Cancer • Solid Tumor

Effects of Chronic S. mansoni Infection on Innate and Adaptive Immune Responses in Olive Baboons Vaccinated with Human Papillomavirus Vaccine (ASTMH 2025) - "Baboons were assigned to three groups: (1) untreated S. mansoni-infected, (2) S. mansoni-infected and treated with Praziquantel, and (3) uninfected controls. All received two doses of the Cervarix HPV vaccine four weeks apart...These findings emphasize the importance of a booster dose for enhanced antibody production and suggest that a delayed HPV-specific whole IgG response in untreated S. mansoni-infected individuals reinforces the need for booster HPV vaccination in endemic regions. The results affirm the vaccine's effectiveness in S. mansoni endemic areas."

Infectious Disease

Human Papillomavirus Vaccine immune responses in an Olive baboon model is not compromised by chronic Schistosoma mansoni infections. (PubMed, AIMS Microbiol) - "Baboons were assigned to three groups: (1) untreated S. mansoni-infected, (2) S. mansoni-infected and treated with Praziquantel, and (3) uninfected controls. All received two doses of the Cervarix HPV vaccine four weeks apart...Gardasil® quadrivalent HPV vaccine antigen was used in both ELISA and PBMC stimulation for cytokine ELISA supernatants...These findings emphasize the importance of a booster dose for strong antibody production and suggest that a delayed HPV-specific whole IgG response in untreated S. mansoni-infected individuals reinforces the need for booster HPV vaccination in endemic regions. The results affirm the vaccine's effectiveness in S. mansoni endemic areas."

Journal • Infectious Disease • Oncology

The Rehabilitation of a Patient with Acute Transverse Myelitis After HPV Vaccination-A Case Report. (PubMed, Diseases) - "We present a case of a 21-year-old woman who developed ATM two weeks following administration of the first dose of the HPV vaccine (Cervarix)...Although no causal link between HPV vaccination and ATM has been established, this case emphasizes the importance of considering post-vaccinal autoimmune phenomena. More importantly, it illustrates the critical role of early, targeted rehabilitation-particularly pelvic floor re-education and neuromodulation-in improving outcomes in patients with significant motor and autonomic deficits."

Journal • CNS Disorders • Immunology • Oncology

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (clinicaltrials.gov) - P4 | N=27945 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2028

Trial completion date • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells. (PubMed, Front Immunol) - "The Gardasil-4® vaccine targets HPV types 6, 11, 16 and 18 and is formulated with amorphous alum. Increased DC signaling, including NOTCH, through AS04 in Cervarix supports cell survival and sustained RNA translation in memory B cells, 7 days post-vaccination. This may enhance adaptive immune cell maturation, providing a mechanism that can lead to improved cross-reactivity."

IO biomarker • Journal • BCL2 • NOTCH2 • TLR4

HVRRICANE: Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • CD4

Human papillomavirus (HPV) vaccine effectiveness against anal HPV-16 and HPV-18 infections among young men who have sex with men visiting the sexual health center of Amsterdam (HPV4M): study protocol of an observational study. (PubMed, BMJ Open) - "We recruit MSM at the Sexual Health Center of Amsterdam, born in 1996-2003, who receive bivalent HPV vaccination (Cervarix) (group 1)...Findings will be presented to stakeholders in immunisation policy and be disseminated through scientific journals and conference presentations. CLINICAL TRIAL INFORMATION SYSTEM 2022-502224-49-00."

Journal • Observational data • Anal Carcinoma • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Frequency, Timing, Burden and Recurrence of Adverse Events Following Immunization After HPV Vaccine Based on a Cohort Event Monitoring Study in the Netherlands. (PubMed, Vaccines (Basel)) - "Background/Objectives: The aim of this study was to systematically assess Adverse Events Following Immunization (AEFI) among children following administration of the human papillomavirus (HPV) vaccine (Cervarix®) included in the Dutch National Immunization Program (NIP) and to characterize the pattern and recurrence risk of AEFI after HPV revaccination...An increased risk of recurrence was seen for AEFI, such as injection site reactions and headache. Furthermore, this study provides insight into the course of AEFI and the extent to which children were affected by these symptoms based on real-world data."

Adverse events • Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Orthopedics • Pain

A Reassessment of Serious Adverse Events After Human Papillomavirus Vaccination in the Nagoya Survey in Japan by Using Incidentality Analysis. (PubMed, Cureus) - "Vaccines were administered using either the bivalent (Cervarix, GlaxoSmithKline, London, UK) or quadrivalent (Gardasil, Merck & Co., Rahway, NJ) HPV vaccine. As this study is based on questionnaire data from 2015, the robustness of the evidence is limited. Thus, to strengthen the evidence derived from this study, future research should be conducted by employing the same incidentality analysis based on up-to-date physician-recorded data with minimized reporting bias, rather than questionnaire-based data, focusing on symptoms rather than disease diagnoses."

Adverse events • Journal • Serious adverse event • Alzheimer's Disease • Cervical Cancer • CNS Disorders • Oncology • Pain • Solid Tumor

HPV Vaccines - An Overview. (PubMed, Indian J Dermatol) - "After this in 2007, Cervarix was approved and finally Gardasil 9 in 2014. This article reviews the currently available vaccines, their indications, adverse effects, contraindications, and epidemiological impact. It also highlights the off label therapeutic uses in various conditions and other potential vaccine candidates."

Journal • Review • Cervical Cancer • Gynecology • Oncology • Solid Tumor

Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports. (PubMed, Hum Vaccin Immunother) - "We evaluated adverse events (AEs) reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) for Cervarix® (bivalent), Gardasil® (quadrivalent), and Gardasil-9® (9-valent) between January 2006 and December 2024. Strengthening provider education in cold-chain management and schedule adherence may further enhance vaccine safety. Continued active surveillance is recommended."

Journal • Real-world evidence • Oncology

Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial. (PubMed, Lancet Infect Dis) - P3 | "Non-inferior antibody responses for the single-dose bivalent HPV vaccine were seen for HPV-18 but not HPV-16, which would be insufficient evidence to motivate regulatory change, even though seropositivity approached 100% in the follow-up phase and the observed antibody concentrations were similar to protective levels seen in previous trials. Trials that directly evaluate protection afforded by single-dose HPV vaccination against persistent HPV infection will definitively address the level of protection afforded by single-dose HPV vaccination."

Head-to-Head • Journal • Human Papillomavirus Infection • Infectious Disease • Oncology

Human papillomavirus vaccine: Success and challenges. (PubMed, J Biosci) - "Cervarix®, Gardasil®, and Gardsil9® are three approved prophylactic vaccines that can effectively provide protection against HPV infection. The development of a therapeutic vaccination coupled with currently available prophylactic vaccines is anticipated to significantly lower morbidity and cancer load globally. This review aims to provide a clear understanding of the molecular basis, immunogenicity, effectiveness, and challenges of current prophylactic vaccines and the future scope of implementing therapeutic vaccines against infection caused by HPV."

Journal • Review • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Paced immune activation by AS04 drives superior cross-protective antibody response in Cervarix (IMMUNOLOGY 2025) - "Description The Gardasil®-4 vaccine targets HPV type 6,11,16 and 18 and is formulated with AlHO9PS-3. This results in delayed activation and sustained proliferation of adaptive immune cells at day 7, relying more on memory T and B cells. A paced immune activation may enhance adaptive immune cell maturation, providing a mechanism for improved cross-reactivity.Keywords: Animals Human; Cells B Cells Dendritic Cells T Cells; Processes Antigen Presentation/Processing"

BCL2 • CD4 • CDK1 • TLR4